Inactive Instrument

Press Releases Lion Biotechnologies Inc OTC Bulletin Board

Equities

LBIO

US53619R1023

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

13/05	Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained	MT
13/05	Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	18/05	AQ
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	14/05	AQ
Iovance Biotherapeutics: Q1 Earnings Snapshot	10/05	AQ
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates	10/05	AQ
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024	01/05	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	30/04	AQ
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting	25/04	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024	22/04	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	20/04	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	25/03	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	23/03	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	04/03	AQ
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer	04/03	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	02/03	AQ
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	29/02	AQ
Iovance Biotherapeutics: Q4 Earnings Snapshot	29/02	AQ
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	29/02	AQ
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024	22/02	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI for Advanced Melanoma	21/02	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI(TM) (lifileucel) for Advanced Melanoma	21/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lion Biotechnologies Inc OTC Bulletin Board

Equities

LBIO

US53619R1023

Press Releases

Filters